Modulation of antitumor immunity by dietary soy and its isoflavone constituents
食用大豆及其异黄酮成分调节抗肿瘤免疫力
基本信息
- 批准号:8579250
- 负责人:
- 金额:$ 31.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-03 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdenocarcinomaAgonistAreaAttentionBiochemicalBiologicalBiological MarkersBloodBreadCancer PatientCell CycleCellsCellular biologyClinical ResearchDataDevelopmentDiagnosisDietDietary InterventionEtiologyEvaluationExperimental NeoplasmsFailureFoodFoundationsFutureGenerationsGenisteinHealthHormonesHumanImmuneImmune responseImmune systemImmunityImmunologic MonitoringImmunomodulatorsImmunosuppressive AgentsImmunotherapyIn VitroIndolentInflammationInflammatoryInterleukin-10Interleukin-6InterventionIsoflavonesLymphocyteMalignant NeoplasmsMalignant neoplasm of prostateMetabolismModelingMusMyelogenousMyeloid CellsNatural Killer CellsOperative Surgical ProceduresPathway interactionsPatientsPeripheral Blood Mononuclear CellPhase I Clinical TrialsPhenotypePhytochemicalPlayPopulationPrevention strategyProcessPropertyProstateProstate Cancer therapyProstatectomyRandomizedRegimenReportingResearchRoleSignal TransductionSignal Transduction PathwaySolidSolid NeoplasmSourceSoybeansStagingStimulusStructure of base of prostateSuppressor-Effector T-LymphocytesT-Cell ProliferationT-LymphocyteTestingTissuesTransforming Growth FactorsTransgenic OrganismsWheatWorkantiangiogenesis therapyarmbasebone healthcancer preventioncancer riskcarcinogenesiscytokinecytotoxicdaidzeinexperiencefeedingimmune functionimprovedin vivo Modelinsightinterestmeetingsmenneutrophilnovelperipheral bloodphase 2 studypreclinical studypreventprostate cancer modelpublic health relevanceresponsesoysoy protein isolatetranslational studytumortumor microenvironmenttumor progression
项目摘要
DESCRIPTION (provided by applicant): Soybeans and the foods derived from them are a rich source of bioactive phytochemicals that promote health. Soy isoflavones are hypothesized to act through various pathways to impact prostate cancer (PCa) progression; however, one area that has received very little focus is the impact of soy components on the immune system. This is of importance with the ongoing development and approval of immune-based therapies for PCa (e.g.; Provenge) and a recent appreciation for the immune system in regulating prostate cancer development. One barrier to optimal anti-tumor immune responses are immunosuppressive myeloid-derived suppressor cells (MDSC). MDSC act through a variety of mechanisms systemically and in the tumor microenvironment. Our group and others have shown that MDSC are a relevant biomarker associated with reduced overall survival in patients with solid tumors and early reports indicate MDSC are elevated in PCa patients. Our preliminary data demonstrate that dietary soy modulates T cell proliferation and the cellular response to pro-inflammatory cytokines in mice. Further, genestein promoted in vitro differentiation of peripheral blood mononuclear cells into neutrophils and inhibited in vitro MDSC generation. We developed a novel soy bread which delivers high levels of isoflavones. This bread was safe and met with favorable compliance in men with PCa experiencing biochemical failure. Compared to baseline, MDSC and pro- inflammatory cytokines were significantly lower in the blood of patients receiving soy bread intervention. These data suggest that the role of dietary soy as an immunomodulator requires further systematic evaluation. We are interested in how dietary soy and its isoflavone constituents modulate signal transduction pathways and immune cell populations relevant to inflammation and prostate cancer. We hypothesize that dietary soy may prevent PCa progression by inhibiting expansion of immunosuppressive cells and reducing the cellular response to pro-inflammatory signals. We will determine how soy isoflavones or their metabolites modulate the differentiation and immunosuppressive function of myeloid cells after in vitro stimulation with pro- inflammatory stimuli. We will also evaluate the effects of dietary sy on MDSC expansion and function in the TRAMP and Hi-myc models of PCa and the ex vivo response of lymphocytes to relevant immune stimuli. A phase I clinical trial will be conducted in men diagnosed with PCa and randomized to receive dietary intervention with soy bread (experimental arm) or wheat bread (control arm) for 4 weeks prior to prostatectomy to evaluate pro-inflammatory cytokines, immune cell markers (e.g. MDSC, T cells, NK cells) and T cell proliferation in peripheral blood at baseline and following intervention and freshly isolated prostate tissue. These studies will provide a comprehensive, translational understanding of how dietary soy and its isoflavone components modulate aspects of immunity relevant to prostate cancer development and progression.
描述(由申请人提供):蚕豆和从它们中提取的食物是促进健康的生物活性植物化学物质的丰富来源。大豆黄酮被假设通过各种途径影响前列腺癌(PCa)的进展;然而,一个很少受到关注的领域是大豆成分对免疫系统的影响。这对于持续开发和批准用于PCa的基于免疫的疗法(例如; Provenge)和最近对免疫系统调节前列腺癌发展的认识。最佳抗肿瘤免疫应答的一个障碍是免疫抑制性髓源性抑制细胞(MDSC)。MDSC通过多种机制在全身和肿瘤微环境中发挥作用。我们的小组和其他人已经表明,MDSC是一个相关的生物标志物,与实体瘤患者的总生存率降低,早期的报告表明,MDSC在PCa患者中升高。我们的初步数据表明,饮食大豆调节小鼠T细胞增殖和细胞对促炎细胞因子的反应。此外,genestein促进外周血单核细胞在体外分化为中性粒细胞,并抑制体外MDSC的产生。我们开发了一种新的大豆面包,它提供了高水平的大豆酮。这种面包是安全的,在经历生化失败的PCa男性中符合良好的依从性。与基线相比,接受大豆面包干预的患者血液中的MDSC和促炎细胞因子显著降低。这些数据表明,膳食大豆作为免疫调节剂的作用需要进一步的系统评价。我们感兴趣的是饮食大豆和它的主要成分如何调节信号转导途径和免疫细胞群相关的炎症和前列腺癌。我们推测,饮食中的大豆可能通过抑制免疫抑制细胞的扩增和减少细胞对促炎信号的反应来预防前列腺癌的进展。 我们将确定大豆异黄酮或其代谢产物如何调节体外促炎刺激后骨髓细胞的分化和免疫抑制功能。我们还将评估饮食sy对PCa的TRAMP和Hi-myc模型中MDSC扩增和功能的影响以及淋巴细胞对相关免疫刺激的离体反应。将在被诊断患有PCa并且在前列腺切除术之前随机接受大豆面包(实验组)或小麦面包(对照组)的饮食干预4周的男性中进行I期临床试验,以评估基线和干预后外周血和新鲜分离的前列腺组织中的促炎细胞因子、免疫细胞标志物(例如MDSC、T细胞、NK细胞)和T细胞增殖。这些研究将提供一个全面的,翻译的理解,如何饮食大豆和它的大豆成分调节免疫方面相关的前列腺癌的发展和进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory B. Lesinski其他文献
Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis
在黑色素瘤模型中靶向血管活性肠肽-血管活性肠肽2型受体(VIP-VPAC)通路可抑制肿瘤生长和肝转移
- DOI:
10.1016/j.canlet.2025.217855 - 发表时间:
2025-09-28 - 期刊:
- 影响因子:10.100
- 作者:
Wenxi Wang;Hua Yang;Tenzin Passang;Yiwen Li;Hanwen Zhang;Shayna E. Jankowski;Fanyuan Zeng;Shuhua Wang;Po-Chih Hsu;Jian-Ming Li;Zihan Chen;Gregory B. Lesinski;Pia R. Mendoza;Ying Li;Cynthia R. Giver;Hans E. Grossniklaus;Edmund K. Waller - 通讯作者:
Edmund K. Waller
Diagnostic and Prognostic Biomarkers of Chronic Pancreatitis: A Conceptual Framework Based on the PRoBE Design
慢性胰腺炎的诊断和预后生物标志物:基于 PRoBE 设计的概念框架
- DOI:
10.1053/j.gastro.2024.02.030 - 发表时间:
2024-06-01 - 期刊:
- 影响因子:25.100
- 作者:
Dhiraj Yadav;Darwin L. Conwell;Stephen J. Pandol;Hanno Steen;Ziding Feng;Liang Li;Dana Andersen;Melena Bellin;Suresh T. Chari;Zobeida Cruz-Monserrate;William E. Fisher;Evan L. Fogel;Christopher E. Forsmark;Phil A. Hart;Gregory B. Lesinski;Walter G. Park;Jo Ann Rinaudo;Jami L. Saloman;Jose Serrano;Temel Tirkes;David C. Whitcomb - 通讯作者:
David C. Whitcomb
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
帕立骨化醇和羟氯喹增强胰腺导管腺癌化疗疗效的机制
- DOI:
10.1016/j.xcrm.2024.101881 - 发表时间:
2025-01-21 - 期刊:
- 影响因子:10.600
- 作者:
Ganji Purnachandra Nagaraju;Madhu Sudhana Saddala;Jeremy B. Foote;Ateeq M. Khaliq;Ashiq Masood;Yuvasri Golivi;Dhana Sekhar Reddy Bandi;Sujith Sarvesh;Sudhir Putty Reddy;Jeffrey Switchenko;Julienne L. Carstens;Mehmet Akce;Cameron Herting;Olatunji B. Alese;Karina J. Yoon;Upender Manne;Manoj K. Bhasin;Gregory B. Lesinski;Vikas P. Sukhatme;Bassel F. El-Rayes - 通讯作者:
Bassel F. El-Rayes
Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer
- DOI:
10.1245/s10434-021-10111-0 - 发表时间:
2021-05-13 - 期刊:
- 影响因子:3.500
- 作者:
Alexander J. Rossi;Tahsin M. Khan;Hanna Hong;Gregory B. Lesinski;Christina Wu;Jonathan M. Hernandez - 通讯作者:
Jonathan M. Hernandez
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions
- DOI:
10.1007/s10555-021-09988-w - 发表时间:
2021-09-01 - 期刊:
- 影响因子:8.700
- 作者:
Cameron J. Herting;Isaac Karpovsky;Gregory B. Lesinski - 通讯作者:
Gregory B. Lesinski
Gregory B. Lesinski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory B. Lesinski', 18)}}的其他基金
Enhancing immune therapy in pancreatic cancer by targeting IL-6
通过靶向 IL-6 增强胰腺癌的免疫治疗
- 批准号:
9331604 - 财政年份:2016
- 资助金额:
$ 31.85万 - 项目类别:
Enhancing immune therapy in pancreatic cancer by targeting IL-6
通过靶向 IL-6 增强胰腺癌的免疫治疗
- 批准号:
10224899 - 财政年份:2016
- 资助金额:
$ 31.85万 - 项目类别:
Modulation of antitumor immunity by dietary soy and its isoflavone constituents
食用大豆及其异黄酮成分调节抗肿瘤免疫力
- 批准号:
9087171 - 财政年份:2013
- 资助金额:
$ 31.85万 - 项目类别:
Modulation of antitumor immunity by dietary soy and its isoflavone constituents
食用大豆及其异黄酮成分调节抗肿瘤免疫力
- 批准号:
8695304 - 财政年份:2013
- 资助金额:
$ 31.85万 - 项目类别:
Translational Research Cancer Centers Consortium Annual Meeting
转化研究癌症中心联盟年会
- 批准号:
8319055 - 财政年份:2012
- 资助金额:
$ 31.85万 - 项目类别:
Evaluating the anti-tumor effects of novel curcumin analogs in melanoma
评估新型姜黄素类似物对黑色素瘤的抗肿瘤作用
- 批准号:
8035970 - 财政年份:2010
- 资助金额:
$ 31.85万 - 项目类别:
Evaluating the anti-tumor effects of novel curcumin analogs in melanoma
评估新型姜黄素类似物对黑色素瘤的抗肿瘤作用
- 批准号:
7897164 - 财政年份:2010
- 资助金额:
$ 31.85万 - 项目类别:
SOCS proteins as inhibitors of immune surveillance in the melanoma microenvironme
SOCS 蛋白作为黑色素瘤微环境中免疫监视的抑制剂
- 批准号:
7510255 - 财政年份:2008
- 资助金额:
$ 31.85万 - 项目类别:
SOCS proteins as inhibitors of immune surveillance in the melanoma microenvironme
SOCS 蛋白作为黑色素瘤微环境中免疫监视的抑制剂
- 批准号:
7683943 - 财政年份:2008
- 资助金额:
$ 31.85万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 31.85万 - 项目类别:














{{item.name}}会员




